IP Library › Granted Patent US 12,285,482
Granted Patent B2
US 12,285,482 · App. 17/810,480 · Granted Apr 29, 2025

Therapeutic vaccine for Hepatitis B virus (HBV) using the HBV PreS1 and/or PreS2, and/or S-HBsAg regions of the HBV envelope protein

Inventors: Edward A. Clark (Seattle, WA); Che-Leung Law (Seattle, WA); Deborah Fuller (Seattle, WA); Michael Gale (Seattle, WA)
Assignees: UNIVERSITY OF WASHINGTON; ABACUS BIOSCIENCE, INC.
A61K39/292A61P31/20C07K16/2878C07K16/2896A61K2039/6056C07K2317/524C07K2317/526C07K2317/56C07K2317/622
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,285,482
App. No.
17/810,480
Granted
Apr 29, 2025
Kind
B2
Abstract

Compositions including a CD180 binding ligand and a linked Hepatitis B antigen and their use are disclosed. The Hepatitis B antigen includes Hepatitis B virus pre-S1 and/or pre-S2 region of the HBV envelope protein (HBVpreS1/S2Ag), L-HBsAg, MHBsAg, S-HBsAg, or antigenic fragments or mutants thereof.

Claims (32)

1. A nucleic acid encoding a polypeptide comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:67 residues 21-697.

2. The nucleic acid of claim 1 , wherein the encoded polypeptide comprises an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:67 residues 21-697.

3. The nucleic acid of claim 1 , wherein the encoded polypeptide comprises an amino acid sequence having at least 98% identity to the amino acid sequence of SEQ ID NO:67 residues 21-697.

4. The nucleic acid of claim 1 , wherein the encoded polypeptide comprises the amino acid sequence of SEQ ID NO:67 residues 21-697.

5. The nucleic acid of claim 1 , wherein the encoded polypeptide comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:67.

6. The nucleic acid of claim 1 , wherein the encoded polypeptide comprises an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:67.

7. The nucleic acid of claim 1 , wherein the encoded polypeptide comprises an amino acid sequence having at least 98% identity to the amino acid sequence of SEQ ID NO:67.

8. The nucleic acid of claim 1 , wherein the encoded polypeptide comprises the amino acid sequence of SEQ ID NO:67.

9. The nucleic acid of claim 1 , wherein the nucleic acid is RNA.

10. The nucleic acid of claim 2 , wherein the nucleic acid is RNA.

11. The nucleic acid of claim 4 , wherein the nucleic acid is RNA.

12. The nucleic acid of claim 8 , wherein the nucleic acid is RNA.

13. An expression vector comprising the isolated nucleic acid of claim 1 operatively linked to a promoter.

14. An expression vector comprising the isolated nucleic acid of claim 4 operatively linked to a promoter.

15. A pharmaceutical composition, comprising

(a) the nucleic acid claim 1 ; and

(b) a pharmaceutically acceptable carrier.

16. A pharmaceutical composition, comprising

(a) the nucleic acid claim 4 ; and

(b) a pharmaceutically acceptable carrier.

17. A pharmaceutical composition, comprising

(a) the nucleic acid claim 8 ; and

(b) a pharmaceutically acceptable carrier.

18. A pharmaceutical composition, comprising

(a) the nucleic acid claim 9 ; and

(b) a pharmaceutically acceptable carrier.

19. A pharmaceutical composition, comprising

(a) the nucleic acid claim 11 ; and

(b) a pharmaceutically acceptable carrier.

20. A pharmaceutical composition, comprising

(a) the nucleic acid claim 12 ; and

(b) a pharmaceutically acceptable carrier.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2024
From: LAW, CHE-LEUNG
To: ABACUS BIOSCIENCE, INC.
Reel/Frame 068627/0687 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2024
From: CLARK, EDWARD A.; FULLER, DEBORAH; GALE, MICHAEL
To: UNIVERSITY OF WASHINGTON
Reel/Frame 068627/0798 →
Continuity (3)
Continuation 16764950
Provisional Application 62587051 · Nov 16, 2017
Related Publication 20230053634A1 · Feb 23, 2023
References Cited (68)
US 10196614B2 · Clark et al. · 2019 [cited by applicant]
US 10563179B2 · Clark et al. · 2020 [cited by applicant]
US 11389532B2 · Clark · 2022 [cited by examiner]
US 20120020965A1 · Chaplin et al. · 2012 [cited by applicant]
US 20130017200A1 · Scheer et al. · 2013 [cited by applicant]
US 20130209395A1 · Weiner et al. · 2013 [cited by applicant]
US 20170260258A1 · Hong et al. · 2017 [cited by applicant]
WO 199704000 · 1997 [cited by applicant]
WO 2009036228 · 2009 [cited by applicant]
WO 2017176319 · 2017 [cited by applicant]
WO 2017176319A1 · 2017 [cited by applicant]
Alving et al. (2012) Adjuvants for human vaccines. Curr Opin Immunol. 24:310-5. [cited by applicant]
Beck et al. (2007) Hepatitis 8 virus replication. World J Gastroenterol WJG. 13:48-64. [cited by applicant]
Bertoletti et al. (2016) Adaptive immunity in H8V infection. J Hepatol. 64:S71-83. [cited by applicant]
Bian et al. (2017) Vaccines Targeting PreS1 Domain Overcome Immune Tolerance in HBV Carrier Mice. Hepatology. Apr. 26. doi:1002/hep.29239. [cited by applicant]
Bruss V. (2007) Hepatitis B virus morphogenesis. World J Gastroenterol. 13:65-73. [cited by applicant]
Chaplin et al. (2013) Targeting antigens to CD180 rapidly induces antigen-specific IgG, affinity maturation and immunologic memory. J Exp Med. 210:2135-46. [cited by applicant]
Chaplin et al. (2011) Anti-CD180 (RP105) activates B cells to rapidly produce polyclonal Ig via aT cell and My088-independent pathway. J Immunol. 187:4199-209. [cited by applicant]
Chappell et al. (2014) Controlling immune responses by targeting antigensto dendritic cell subsets and B Cells. Int Immunol. 26:3-11. [cited by applicant]
Chen et al. (2016) Selection of affinity-improved neutralizing human scFv against HBV PreS1 from CDR3 VHNL mutant library. Biologicals. July;44(4):271-5. [cited by applicant]
Chi et al. (2009) Broadly neutralizing anti-HBV antibody binds to non-epitope regions of preS1. FEBS Lett. 583:3095-100. [cited by applicant]
Clark et al. (1989) Activation of human B cells. Comparison of the signal transduced by IL-4 to four different competence signals. J Immunol. 143:3873-80. [cited by applicant]
Coffman et al. (2010) Vaccine adjuvants: putting innate immunity to work. Immunity. 33:492-503. [cited by applicant]
Dion et al. (2013) Adena-associated virus-mediated gene transfer leads to persistent hepatitis B virus replication in mice expressing HLA-A2 and HLA-DR1 molecules. J Virol. May;87(10):5554-63. [cited by applicant]
Eng et al. (2013) The potential of 1018 ISS adjuvant in hepatitis 8 vaccines: HEPLISAV™. Hum Vaccin Immunother. 9:1661-72. [cited by applicant]
Ferrari et al. (1989) The preS1 antigen of hepatitis B virus is highly immunogenic at the T cell level in man. J Clin Invest. 84:1314-9. [cited by applicant]
Gerlich WH. (2015) Prophylactic vaccination against hepatitis 8: achievements, challenges and perspectives. Med MicrobiolImmunol. 204:39-55. [cited by applicant]
Hebeis et al. (2005) Vav proteins are required forB-lymphocyte responses to LPS. Blood. 106:63540. [cited by applicant]
Hebeis et al. (2004)Activation of virus-specific memory B cells in the absence of T cell help. J Exp Med. 199:593-602. [cited by applicant]
Hepatitis 8 Vaccines (2004) Releve epidemiologique hebdomadaire I Section d'hygiene du Secretariat de la Societe des Nations = Weekly epidemiological record I Health Section of the Secretariat of the League of Nations. … [cited by applicant]
Jilg W. (1998) Novel hepatitis 8 vaccines. Vaccine. 16 Suppi:S65-8. [cited by applicant]
Kim et al. (2009) Hepatitis 8 vaccination in HIV-infected adults: current evidence, recommendations and practical considerations. International journal of STD & AIDS. [cited by applicant]
Kim WR. (2009) Epidemiology of hepatitis B in the United States. Hepatology. 49:S28-34. [cited by applicant]
Krawczyk et al. (2014) Induction of a robust T- and B-cell immune response in non- and low-responders to conventional vaccination against hepatitis B by using a third generation PreS/S vaccine. Vaccine. 32:5077-82. [cited by applicant]
Kubba (2003) et al. Non-responders to hepatitis 8 vaccination: a review. Communicable disease and public health PHLS. 106-12. [cited by applicant]
Lavanchy D. (2004) Hepatitis 8 virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hep. 11:97-107. [cited by applicant]
Li W. (2015) NTCP is receptor for HBV The hepatitis 8 virus receptor. Annu Rev Cell Dev Bioi. 31:125-47. [cited by applicant]
Liang al. (2011) Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy. Aliment Pharmacal Ther. 34:344-52. [cited by applicant]
Loudon et al. (2010) GM-CSF increases mucosal and PA, GM-CSF increases mucosal and systemic immunogenicity fo an H1N1 influenza DNA vaccine administered into the epidermis of non-human primates. PLoS One. 5:e11021. [cited by applicant]
Luckhaupt et al. (2008) Deaths due to bloodborne infections and their sequelae among health-care workers. Am J Ind Med. 51:812-24. [cited by applicant]
Madalinski et al. (2001) Antibody responses to preS components after immunization of children with low doses of BioHepB. Vaccine. Oct. 12, 2020(1-2):92-7. [cited by applicant]
Maxon et al. (2011) The next decade of vaccines: societal and scientific challenges. Lancet. 378:348-59. [cited by applicant]
Menendez-Aria et al. (2014) Nucleoside/nucleotide analog inhibitors of hepatitis 8 virus polymerase: mechanism of action and resistance. Curr Opin Viral. 8C:1-9. [cited by applicant]
Mitchell et al. (2011) The increasing burden of imported chronic hepatitis 8—United States, 1974-2008. PLoS One. 6:e27717. [cited by applicant]
Miyake et al. (1994) Murine B cell proliferation and protection from apoptosis with an antibody against a 105-kD molecule: unresponsiveness of X-linked immunodeficient B cells. J Exp Med. 180:1217-24. [cited by applicant]
Miyake et al. (1995) RP105, a novel B cell surface molecule implicated in B cell activation, is a member of the leucine-rich repeat protein family. J Immunol. 154:3333-40. [cited by applicant]
Ni et al. (2014) Hepatitis 8 and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology. Apr 146(4):1070-83. [cited by applicant]
Ohto et al. (2011) Crystal structures of mouse and human RP105/MD-1complexes reveal unique dimer organization of the toll-like receptor family. J Mol Bioi. Nov. 4:413(4):815-25. [cited by applicant]
Ott et al. (2012) Global epidemiology of hepatitis 8 virus infection: new estimates of age-specific H8cAG seroprevalence and endemicity. Vaccine. 30:2212-9. [cited by applicant]
Perz et al. (2006) The contributions of hepatitis 8 virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 45:529-38. [cited by applicant]
Ramos H.J. (2011) RIG-I like receptors and their signaling crosstalk in the regulation of antiviral immunity. Curr Opin Virol.1:67-76. [cited by applicant]
Rendi-Wagner et al. (2006) Comparative immunogenicity of a PreS/S hepatitis 8 vaccine in non and low responders to conventional vaccine. Vaccine. 24:2871-9. [cited by applicant]
Schultz et al. (2017) The RP105/MD-1 complex: molecular signaling mechanisms and pathophysiological implications. J Leukoc Bioi. Jan:101(1):183-192. [cited by applicant]
Shimazu et al. (1999) MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor4. J Exp. Med. 189:1777-82. [cited by applicant]
Suthar et al. (2013) West Nile virus infection and immunity. Nat. Rev Microbiol. 11:115-128. [cited by applicant]
Thai et al. (2012) Convergence and coevolution of hepatitis 8 virus drug resistance. Nat Commun. 3:789. [cited by applicant]
Toita et al. (2015) Applications of human hepatitis B virus preS domain in bio- and nanotechnology. World J Gastroenterol. Jun. 28:21(24):7400-11. [cited by applicant]
Valatine et al. (1988) Antibody to a novel 95-kDa surface glycoprotein on human B cells induces calcium mobilization and B cell activation. J Immunol. 140:4071-8. [cited by applicant]
Wang et al. (2014) Immunotherapeutic interventions in chronic hepatitis 8 virus infection: a review. J Immunol Methods. May:407:1-8. [cited by applicant]
Wasley et al. (2010) The prevalence of hepatitis 8 virus infection in the United States in the era of vaccination. J Infect Dis. 202:192-201. [cited by applicant]
Weinbaum CM, (2008) Recommendations for identification and public health management of persons with chronic hepatitis 8 virus infection. Centers for Disease Control and Prevention (CDC). MMWR Recomm. Rep 57(RR-8):1-20. [cited by applicant]
Wiegand et al. (2010) Management of chronic hepatitis 8: status and challenges beyond treatment guidelines. Semin Liver Dis. 30:361-377. [cited by applicant]
Yazawa et al., (2003) CD19 regulates innate immunity by the toll-like receptor RP105 signaling in B lymphocytes. Blood. 102:1374-80. [cited by applicant]
Yoon et al. (2011) An unusual dimeric structure and assembly for TLR4 regulator RP105-MD-1. Nat Struct Mol Bioi. 2. Aug. 21:18(9):1028-35. [cited by applicant]
The International Search Report (ISR) with Written Opinion for PCT/US2018/061218 dated Feb. 5, 2019, pp. 1-11. [cited by applicant]
LLoyd et al. Protein Engineering, Design & Selection 22: 159-168 (Year: 2009). [cited by applicant]
Edwards et al., J Mol Biol. 334(1 ): 103-118 (Year: 2003). [cited by applicant]
Rudikoff et al., Proc. Natl. Acad. Sci. USA, 79:1979-1983 (Year: 1982). [cited by applicant]